Gene Therapy Offers New Hope for Duchenne Muscular Dystrophy Patients

Gene therapy approach developed offers new hope for those with Duchenne muscular dystrophy by restoring the full-length dystrophin protein.

Researchers have achieved a significant breakthrough in developing a new gene therapy approach that restores the full-length dystrophin protein. This advancement could pave the way for new treatments for individuals with Duchenne muscular dystrophy (DMD) ().

The study, recently published in Nature Communications, demonstrates the effectiveness of their novel gene therapy technology in improving muscle tissue and overall strength in mice models with Duchenne muscular dystrophy.

Muscular Dystrophy
Overview about muscular dystrophy, a muscle disease characterized by muscle weakness and muscle wasting.

‘#Duchennemusculardystrophy (DMD) primarily affects boys, with symptoms typically appearing between the ages of 2 and 5. ’

Duchenne Muscular Dystrophy: New Insights

Duchenne muscular dystrophy is a genetic disorder caused by mutations in the DMD gene, resulting in a lack of the protein dystrophin. This deficiency leads to progressive muscle weakness and loss of muscle tissue over time. Patients with the disease experience impaired mobility, heart and lung problems, and ultimately a shortened life expectancy.

“Current gene therapy for Duchenne muscular dystrophy utilizes a truncated version of dystrophin,” said Renzhi Han, PhD, senior author of the study and professor of pediatrics at the IU School of Medicine. “Unfortunately, this option doesn’t fully protect the muscles because it lacks many important functional domains of full-length dystrophin."

While the U.S. Food and Drug Administration recently approved a micro-dystrophin gene therapy for Duchenne muscular dystrophy, Han said the therapeutic outcomes have been less satisfactory than expected.

ELEVIDYS Gene Therapy Shows Promise for Duchenne Muscular Dystrophy
Positive results observed in Duchenne muscular dystrophy patients undergoing gene therapy mark a breakthrough in Illinois medical treatment.

Building on their experience using adeno-associated virus methods to deliver extra-large therapeutic genes into cells, Han and his team at the Herman B Wells Center for Pediatric Research developed a triple-adeno-associated virus vector system to deliver a complete version of the dystrophin protein into the muscles.

"We optimized and tested our new three-vector system to make sure it produced and assembled the full-length dystrophin protein effectively," Han said. "Our data confirmed we successfully restored full-length dystrophin in both the skeletal and heart muscles of mice with DMD, leading to significant improvements in their muscle health, strength and function.”

New Chapter for Duchenne Muscular Dystrophy Treatment
FDA approval of a novel anti-inflammatory drug provides a hopeful treatment for Duchenne muscular dystrophy.

Han has filed a provisional patent application for his triple-adeno-associated virus vector system and is collaborating with the IU Innovation and Commercialization Office to advance the treatment toward market availability. He is also seeking additional funding so patients with Duchenne muscular dystrophy have access to promising new treatment options.

"I believe this new gene therapy approach offers significant advantages to patients compared to what they currently have available, and I'm eager to get it into further clinical development," he said.

Test Your Knowledge on Gene Therapy
Gene Therapy - Potential Treatment for Incurable Diseases Gene therapy is a novel procedure in which genetic material is introduced into a patient’s cells to replace a faulty gene in order to try and cure disease. It holds promise in ...

Reference:

Systemic delivery of full-length dystrophin in Duchenne muscular dystrophy mice - (https://www.nature.com/articles/s41467-024-50569-6)

Source-Eurekalert